Background. A Clinical phenomenon that has historically been categorized as a condition where the heart's ability to pump and fill with blood is diminished is known as a Heart failure (HF), which is still the world's number one cause of death.
Aim of work. Is to study Cyclophilin- A and evaluate its role and its clinical significance in identifying the patients with heart failure diseases.Methods. On “one hundred and twenty" individuals this work was done, twenty of them were healthy persons (control set), while the other individuals who were recruited from the heart failure clinic and CCU, NHI were divided into two sets, one of both was includes fifty Egyptian HF post myocardial infraction patients (HFpMI), while the left fifty patients were Egyptian HF without MI patients (HFwMI). Cyclophilin-A (CypA) level was assayed by using ELISA technique. Results. Study of lipid profile, cardiac marker for HF diagnosis (proBNP), inflammatory markers (hsCRP and IL-18) and CypA showed that an increasing in the mean value of them in studied groups when compared with control group.Conclusion: The present study showed a significantly increased levels of CypA (P- value < 0.05) in subjects that had previously diagnosed as heart failure patients, suggesting its role in accelerating heart failure progression. It may be considered as biomarker for heart failure and it is reasonable to assume that it could be a target for therapeutic treatment in near future.